Based on such evidence, development of strategies to decrease the oligomerisation and aggregation of α-syn might be promising in particular for PD patients, heterozygotes or homozygotes for SNCA mutations, or gene multiplication. The gene discussed is SNCA; the disease is Parkinson disease.